Glaukos (NYSE:GKOS) COO Sells $1,340,384.64 in Stock

Glaukos Corporation (NYSE:GKOS) COO Joseph Gilliam sold 10,498 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $127.68, for a total value of $1,340,384.64. Following the completion of the transaction, the chief operating officer directly owned 92,366 shares in the company, valued at $11,793,290.88. The trade was a 10.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Glaukos Trading Up 3.6%

GKOS traded up $4.31 during mid-day trading on Monday, reaching $124.29. The stock had a trading volume of 872,424 shares, compared to its average volume of 736,399. The firm’s fifty day simple moving average is $111.25 and its two-hundred day simple moving average is $96.29. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $161.78. The stock has a market capitalization of $7.14 billion, a P/E ratio of -80.71 and a beta of 0.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. The firm had revenue of $133.54 million for the quarter, compared to analysts’ expectations of $122.55 million. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The company’s revenue was up 38.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.28) earnings per share. On average, equities analysts predict that Glaukos Corporation will post -1.08 EPS for the current year.

Analyst Ratings Changes

GKOS has been the subject of several recent research reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $138.00 price objective on shares of Glaukos in a research report on Friday, January 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research note on Thursday. Piper Sandler reaffirmed an “overweight” rating and set a $165.00 price target on shares of Glaukos in a research report on Wednesday, January 14th. Stifel Nicolaus increased their price target on shares of Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Stephens lifted their target price on shares of Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 2nd. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $131.38.

Institutional Investors Weigh In On Glaukos

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP boosted its position in Glaukos by 10.4% during the third quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock valued at $292,004,000 after buying an additional 336,266 shares during the period. Primecap Management Co. CA grew its holdings in shares of Glaukos by 23.3% during the third quarter. Primecap Management Co. CA now owns 2,253,788 shares of the medical instruments supplier’s stock valued at $183,796,000 after buying an additional 425,790 shares during the last quarter. State Street Corp lifted its stake in Glaukos by 5.3% during the 2nd quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock valued at $215,914,000 after acquiring an additional 105,972 shares during the period. Ameriprise Financial Inc. lifted its holdings in Glaukos by 3.5% in the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock valued at $206,503,000 after acquiring an additional 68,497 shares during the period. Finally, Alliancebernstein L.P. increased its stake in shares of Glaukos by 38.5% in the 3rd quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock worth $141,365,000 after purchasing an additional 481,620 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.